No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

近日，厦门大学生命科学学院刘亮教授团队在《Nucleic Acids Research》期刊上在线发表了题为“DNA target binding-induced pre-crRNA processing in type II and V CRISPR-Cas ...

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

"CRISPR is used to switch off a random gene in each cell," explains Schmid-Burgk. "We then enrich the cells in which a specific biological process is altered, and identify the genes switched off." ...

[v] The Cas9 enzyme has been the preferred tool for cutting DNA since the advent of CRISPR, but it’s not necessarily the best choice for all gene-editing applications. One challenge of Cas9 is that it ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

The launch of Casgevy represents a pivotal moment for CRISPR Therapeutics. While initial uptake has been described as slow due to the lengthy treatment process, analysts note that the increase in ...

Today’s headlines highlight critical developments in genetic medicine, global politics, and the latest updates from the ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...